This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Paclitaxel trevatide
DrugBank Accession Number
DB06171
Background

Three paclitaxel molecules linked by a cleavable succinyl ester linkage to a brain peptide vector, Angiopep-2, conjugate named ANG1005.

Type
Biotech
Groups
Investigational
Synonyms
  • Paclitaxel trevatide
External IDs
  • ANG-1005
  • ANG1005

Pharmacology

Indication

Investigated for use/treatment in brain cancer.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel trevatide.
AmsacrineThe risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Paclitaxel trevatide.
AnastrozoleThe risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Paclitaxel trevatide.
Arsenic trioxideThe risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Paclitaxel trevatide.
BevacizumabThe risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel trevatide.
BleomycinThe risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Paclitaxel trevatide.
BortezomibThe risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Paclitaxel trevatide.
BusulfanThe risk or severity of cardiotoxicity can be increased when Busulfan is combined with Paclitaxel trevatide.
CabazitaxelThe risk or severity of cardiotoxicity can be increased when Paclitaxel trevatide is combined with Cabazitaxel.
CapecitabineThe risk or severity of cardiotoxicity can be increased when Capecitabine is combined with Paclitaxel trevatide.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
8P77G99D3P
CAS number
1075214-55-9

References

General References
Not Available
Wikipedia
Paclitaxel_trevatide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentHER 2 Negative Breast Cancer / Leptomeningeal Carcinomatosis / Leptomeningeal Metastases / Tumors Metastatic to Brain1
2CompletedTreatmentBreast Cancer / Tumors Metastatic to Brain2
2CompletedTreatmentGlioblastoma Multiforme (GBM) / Gliomas / Recurrent Brain Tumors1
2TerminatedTreatmentNon-small Cell Lung Cancer (NSCLC) With Brain Metastases1
1CompletedNot AvailableAdvanced Solid Tumors With and Without Brain Metastases1
1CompletedNot AvailableRecurrent or Progressive Malignant Glioma1
Not AvailableNo Longer AvailableNot AvailableAnaplastic Astrocytoma (AA) / Anaplastic Oligodendroglioma (AO) / Breast Cancer With Recurrent Brain Metastases / Leptomeningeal Carcinomatosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at March 19, 2008 16:15 / Updated at February 21, 2021 18:52